IMM-124E – Demonstrates Antiviral T-Cell Immunity
October 08, 2021 06:00 ET
|
Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
Immuron Director resignation
September 23, 2021 23:00 ET
|
Immuron Limited
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron planned Acquisition of R&D Vaccine Company
September 23, 2021 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
May 13, 2021 06:00 ET
|
Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
January 11, 2021 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral...
Immuron SARS-CoV-2 Research Agreement with Monash University
December 15, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.A New...
Immuron Receives AUD $358,280 R&D Tax Concession Refund
November 24, 2020 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
November 11, 2020 06:00 ET
|
Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
July 23, 2020 12:45 ET
|
Immuron Limited
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing...